Romidepsin (FK228, Depsipeptide)

目录号:S3020 别名: FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide) Chemical Structure

Molecular Weight(MW): 540.7

Romidepsin (FK228, Depsipeptide)是一种有效的HDAC1HDAC2抑制剂,无细胞试验中IC50分别为36 nM和47 nM。

规格 价格 库存 购买数量  
RMB 1285.83 现货
RMB 3910.79 现货
RMB 5710.89 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的3个实验数据:

  • An HIV-Gag-SLYNTVATL-specific CTL clone was labeled with Alexa-Fluor555 conjugated cholera toxin subunit B either cultured with 500 nM SAHA or 25 nM romidepsin for 20 hours, or maintained as an untreated control. These effector cells were combined with SLYNTVATL peptide pulsed target cells, matched on the restricting allele, in a collagen matrix medium containing sytox green viability dye. These mixtures were then plated in three separate wells of an 8-well cover slip and imaged by time-lapse brightfield and fluorescent microscopy. A. Shown are representative fields of view from the no treatment (upper panel), 500 nM SAHA (middle panel), and 25 nM romidepsin (lower panel) conditions advancing in time from left to right. Time stamps are given in hh[ratio]mm format. Clones described in the results are indicated with yellow arrows and killed target cells are indicated with white arrows in the upper right panel.

    PLoS Pathog 2014 10(8), e1004287. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    PLZF-RARa–nonexpressing and -expressing PLZFRARβ3 cells were treated with 5 nmol/L romidepsin for the indicated time points. Induction of the DNA DSB marker γH2AX was measured by Western blotting. β-Actin was used as a loading control.

    Mol Cancer Ther 2013 12(8), 1591-604. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • Effects of combination of bort/romidepsin on HDAC6 inhibition and activation of ER stress signaling. HA cells were treated with combination of 15 nM bortezomib and 5 nM romidepsin or either drug alone for 24 hr. Expression of CHOP/GADD153 (green signals) and cleaved PARP (red signals) was detected by immunofluorescent staining. DAPI (blue signals) stained the cell nuclei.

    Int J Cancer 2014 135(12):2950-61. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 Romidepsin (FK228, Depsipeptide)是一种有效的HDAC1HDAC2抑制剂,无细胞试验中IC50分别为36 nM和47 nM。
特性 Romidepsin对I型HDAC的抑制作用明显强于对II型HDAC的抑制。
靶点
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
体外研究

Romidepsin抑制NSCLC细胞系生长,IC50范围从1.3 ng/mL到4.9 ng/mL。 Romidepsin可以降低Erlotinib对NSCLC细胞系的IC50值, 增加NSCLC细胞系对Erlotinib的敏感性[1]。Romidepsin处理72小时可以抑制6/6 人 NB 肿瘤细胞系的生长,而 NIH3T3细胞系并不受影响。 Romidepsin对于单拷贝或N-myc 多拷贝的NB细胞系以及含有正常或突变的p53 和含有Alk突变体的细胞系都有选择性的细胞毒性,这种毒性具有剂量依赖的特性。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 MnPLR4VtdCCYaXHibYxqfHliQYPzZZk> Mn;lNk42NTF3IH7N MYe3NkBp NILtSY5qdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NGPPfI0zPTd7MEmwOy=>
U2932  NX;jV2R[S2WubDDWbYFjcWyrdImgRZN{[Xl? NVm4RohiOi53LUG1JI5O Mlf4O|IhcA>? M13Qeolv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? NGGwN|gzPTd7MEmwOy=>
OCI-LY7 NIm4[IxE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NEDpZpIzNjVvMUWgcm0> M4[zZ|czKGh? NEL0bG9qdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NW\SSZNKOjV5OUC5NFc>
Farage NIP0UnVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NHXNeVEzNjVvMUWgcm0> Mlq1O|IhcA>? MWfpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh NYeySmJLOjV5OUC5NFc>
LY7/EBV M13YXmNmdGxiVnnhZoltcXS7IFHzd4F6 MkXoNk42NTF3IH7N M3qz[lczKGh? NHLFSJFqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NXLuNYdmOjV5OUC5NFc>
U2932/EBV NYi1ZWZUS2WubDDWbYFjcWyrdImgRZN{[Xl? M3ywclIvPS1zNTDuUS=> MoLsO|IhcA>? NVqwU5RGcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= NEHBNXgzPTd7MEmwOy=>
HCT116 NIDEWJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVO1MVUxODBibl2= NX3tOI4zOjRiaB?= NH71OppFVVOR NHPVdmhqdmS3Y3XzJINmdGxiZHXheIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> NX\Hfo1mOjV2OUK1NVU>
ACH-2 M3\uU2Z2dmO2aX;uJGF{e2G7 MUGxMVkhdk1? NXXOTY9XOjRiaB?= MUHpcoR2[2W|IFjJWk0yKEWwdjDlfJBz\XO|aX;u Ml;WNlUyPDl2Nke=
MCF-10A MoLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXhTWM2OD1yLkG3xtExNjBzIH7N NV:5UWFKOjR7NUS4OVY>
MCF-7 M{K0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXab4xKSzVyPUGuNVDDuTBwMkCgcm0> NXj5SWNFOjR7NUS4OVY>
SK-BR-3 NHTQ[JJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzGOHZKSzVyPUGuNFDDuTBwM{Wgcm0> NE\NS|czPDl3NEi1Oi=>
MDA-MB-231 Mk\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkf1TWM2OD1yLk[4xtExNjF2IH7N NGjNeIEzPDl3NEi1Oi=>
PC3 MkThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjuc4NKSzVyPUGuOlXDuTBwM{Wgcm0> M2flcVI1QTV2OEW2
HCT116 NYr3TIpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUX5bFdsUUN3ME2xMlAxyrFyLkCwJI5O M3rufFI1QTV2OEW2
HCT116-p21-/- M3;se2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TsSmlEPTB;MT6yOuKyOC5|NzDuUS=> M2DoeFI1QTV2OEW2
S1 NGWwZnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TiRmlEPTB;Nz62O:KyOC5{OTDuUS=> MX[yOFk2PDh3Nh?=
SW620 M2XF[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\Be|hKSzVyPUCuPVPDuTBwMkmgcm0> Mn\sNlQ6PTR6NU[=
LOX-IMVI MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DkNmlEPTB;MD64O:KyOC5yMzDuUS=> MkHnNlQ6PTR6NU[=
UACC-62 M3nZZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrJOXRKSzVyPUCuOVbDuTBwMU[gcm0> MmXpNlQ6PTR6NU[=
MDA-MB-435 NHTM[m1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jwZmlEPTB;MD65NOKyOC5yNjDuUS=> NWHoUVZ6OjR7NUS4OVY>
SF-295 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTBwOElCtVAvOTVibl2= M4\welI1QTV2OEW2
A549 NFnRd2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DjRmlEPTB;MT6yOuKyOC5{NDDuUS=> NUP4cpFzOjR7NUS4OVY>
H460 M1q1fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPXXmJKSzVyPUKuOVjDuTBwOECgcm0> MUSyOFk2PDh3Nh?=
EKVX NUDpO5BOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnJXW5RUUN3ME2xMlM{yrFyLkO0JI5O MVqyOFk2PDh3Nh?=
H146 Ml;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFL3WYNKSzVyPUCuNlLDuTBwMEegcm0> NGrNTIozPDl3NEi1Oi=>
H526 NWrOeW5pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLiTWM2OD1yLkG1xtExNjB|IH7N MWSyOFk2PDh3Nh?=
HuT-78 NEj2dWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrrWmRvUUN3ME2xMlc{yrFyLkS0JI5O NIm2SYEzPDl3NEi1Oi=>
HA NV7wb2szT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHxN5RXOC54MkWtNVBvVQ>? NYq3bpdJPDhiaB?= MV\pcoR2[2W|IHGgd4lodmmoaXPhcpRtgSC|dILvcodmeiCrbnjpZol1cW:wIH;mJINmdGxicILvcIln\XKjdHnvckBkdy22cnXheIVlKHerdHigZo9zfGW8b33pZi=> NVf4ZWF3OjR5N{G1NVA>
MS-275 NVnNNpBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlj6NE43OjVvMUDuUS=> NWDFXHYyPDhiaB?= M1TTTIlv\HWlZYOgZUB{cWewaX\pZ4FvfGy7IIP0do9v\2W{IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vKGOxLYTy[YF1\WRid3n0bEBjd3K2ZYrvcYlj MmTiNlQ4PzF3MUC=
CD4 T NEjxbIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmD0OFghcA>? NXvobWE2TUN3ME20MlXDuTFwMDDuUS=> Mli1NlQ4OjJ2NUS=
CD4 T MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HHWlQ5KGh? NUXLfZJwS0N3ME2xNFfDuTF{NjDuUS=> Mn\JNlQ4OjJ2NUS=
CD4+ T NGDCb5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjPWnVGSzVyPUOgcm0> MV6yOFQ6PTFyNR?=
A549 Mn\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\0NVDjiJNzMEFCpI5O M3;DSlI1NzN4L{S4JIg> NGrObGdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NH;UXmIzPDR6NUe5PS=>
JJN3 Mo\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\p[3BCOjRxNEigbC=> M4jIcGVEPTB:MfMAjY5OQyB2OPMAjYg> MXyyOFA{ODF3MB?=
OPM-2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjDeI0zPC92ODDo NI[2N3pGSzVyc{2x5qCKdk19IES45qCKcA>? NGT0epozPDB|MEG1NC=>
RPMI-8226 M3fP[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mon0NlQwPDhiaB?= Mmn5SWM2OHN;MT645qCKdk19IES45qCKcA>? MoHlNlQxOzBzNUC=
U266 NUfZ[XBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVWyOE81QCCq MnXnSWM2OHN;MUFihKlvVTtiNElihKlp NFvDXmczPDB|MEG1NC=>
CA46 MVvBdI9xfG:|aYOgRZN{[Xl? NGT0N|c3KGh? MmrTbY5lfWOnczDicJVvfCCjcH;weI9{cXN? MX2yN|k3PjF4NB?=
DG75 NXHPb4xoSXCxcITvd4l{KEG|c3H5 MmfGOkBp MXrpcoR2[2W|IH7vJIFxd3C2b4Ppdy=> MoPlNlM6PjZzNkS=
Ramos M1vWOmFxd3C2b4Ppd{BCe3OjeR?= M{fhNlYhcA>? NU[xWVhucW6mdXPld{BmgHSnboPpeoUh[XCxcITvd4l{ MXqyN|k3PjF4NB?=
ST486 MlHGRZBweHSxc3nzJGF{e2G7 NU\Ed2V[PiCq NEK4PVRqdmS3Y3XzJIV5fGWwc3n2[UBieG:ydH;zbZM> NVm0NpRWOjN7Nk[xOlQ>
HuT78 NHrNNpZCeG:ydH;zbZMhSXO|YYm= NIjYclcyNzFyL{GwNEBvVQ>? MVq0PEBp NVH6W|JicW6mdXPld{BieG:ydH;zbZMh[XRiMTDuUS=> NFnsVmQzOzV|MkezNi=>
DpVp35 MYjBdI9xfG:|aYOgRZN{[Xl? M1P6WlEwOTBxMUCwJI5O NELkco41QCCq MV;pcoR2[2W|IHLseY51KGGyb4D0c5Nqew>? MoPyNlM2OzJ5M{K=
DpVp50 MmrtRZBweHSxc3nzJGF{e2G7 NVO3SlU6OS9zMD:xNFAhdk1? MoXxOFghcA>? M1HhcIlv\HWlZYOgZox2dnRiYYDvdJRwe2m| MYWyN|U{Ojd|Mh?=
DpP75  M4XLRmFxd3C2b4Ppd{BCe3OjeR?= M3nVS|EwOTBxMUCwJI5O NF\KRYo1QCCq MXHpcoR2[2W|IHLseY51KGGyb4D0c5Nqew>? MUeyN|U{Ojd|Mh?=
SKOV-3 NHXGNlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEf1cG0y6oDVMkDuUS=> MmXxO|IhcA>? NWCwRVNkTE2VTx?= NWjo[m01emWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? MnnBNlMxOTB|NEi=
Brca1 WT M33afWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITLVo4y6oDVMkDuUS=> NV3VN4J{PzJiaB?= NWjw[XNyTE2VTx?= NWjHcoNqemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? MVWyN|AyODN2OB?=
Brca1 Null NX\kPGk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUSx5qCUOjCwTR?= MnXlO|IhcA>? NHzweIlFVVOR M1mw[5Jm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv NGDBU5YzOzBzMEO0PC=>
OVCAR-8  NVXoeJBYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzLe4Yy6oDVMkDuUS=> Mn3BO|IhcA>? NYXpNYU{TE2VTx?= MV;y[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGGub37lJIFv\CClb33ibY5m\CC5aYToJINqe3CuYYTpci=> MV[yN|AyODN2OB?=
NCI/ADR-RES NXTCTYVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknENgKBmzJybl2= MUm3NkBp M3zyRmROW09? NEH0[2Vz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? NH;QT4IzOzBzMEO0PC=>
HCT116 NHvTNXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVK1JI5ONTVyIN88US=> M3X5SlI1KGh? MmPPSG1UVw>? M2XpOYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz NFXySHIzOjl{NEm1PC=>
RKO Mk\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFm4VJM2KG6PLUWwJO69VQ>? MmrqNlQhcA>? MkfkSG1UVw>? Mn2xbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> MVuyNlkzPDl3OB?=
CO115 NFjzcZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHwNWpOPSCwTT21NEDPxE1? M{H0d|I1KGh? NXTpRpl5TE2VTx?= MW\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> M2TLRVIzQTJ2OUW4
HFS MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV[wTGlqPSCwTR?= MmP1NlQwPDhxN{KgbC=> NFfKPXlqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lMYRmeGWwZHXueIx6 MoD6NlIyODZ{OEK=
LNCaP MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3ycnhUPSCwTR?= MYCyOE81QC95MjDo NFTIO5JqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lMYRmeGWwZHXueIx6 MV2yNlExPjJ6Mh?=
A549 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\IOUBvVQ>? M2S3SVI1NzR6L{eyJIg> MnHtbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZT3k[ZBmdmSnboTsfS=> M3m0d|IzOTB4Mkiy
697  NI[2cVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLQTWM2OOLCiU5ihKkzNjYEoH7N MkTuNlE2Ozh{MU[=
697-R M3v1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jUW2lEPTEkgJm95qCKQC54wrDuUeKh MmTiNlE2Ozh{MU[=
HUT78 NUfuVGVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXX6RolDUUN3ME2xJI5O MWeyNVE6QDV2NR?=
THJ-16T MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnz4NUBvVQ>? MlXJNlQhcA>? MkO5bY5pcWKrdIOgZ4VtdCCpcn;3eIg> NXvKS5Q1OjB6MUC1Olg>
HCT116 NGnmeIpHfW6ldHnvckBCe3OjeR?= MWKyNEBvVQ>? NI[wXnE5KGh? MmHqcY9lfWyjdHXzJJRz[W6|Y4LpdJQhdGW4ZXzzJIZweiCqdX7kdoVleyCxZjDn[Y5meyCrbjDlbZRp\XJiZHny[YN1cW:w NGO3WHUzODd|OUS1OC=>
B104  M2fWPWZ2dmO2aX;uJGF{e2G7 MoHKNkBvVQ>? M2TQT|I1NzR6L{eyJIg> Ml\sbY5kemWjc3XzJJRp\SC|dYLmZYNmKGW6cILld5Nqd25ib3[gR2QzOMLi MX[yNFY5PjVyNR?=
HL-60  MnTLR5l1d3SxeHnjbZR6KEG|c3H5 M1TMZ|EuPTByIH7N MlPENlQhcA>? NX;WZm5icW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= MVmyNFYzPDF4Mx?=
HP100 MXLDfZRwfG:6aXPpeJkhSXO|YYm= M2rBU|EuPTByIH7N MoH2NlQhcA>? NGnaSnVqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi MYOyNFYzPDF4Mx?=
HL-60  NX6wcFJ4TnWwY4Tpc44hSXO|YYm= NFjZXmoyOCCwTR?= Mlr5OE83NzF4IHi= NVzTNXdjcW6mdXPld{B1cGViZ3Xu[ZJifGmxbjDv[kBpgWS{b3flckBx\XKxeHnk[UBnem:vIETo NYq3Om15OjB4MkSxOlM>
HP100 NF\pSWFHfW6ldHnvckBCe3OjeR?= MVyxNEBvVQ>? NH\4eVE1NzZxMU[gbC=> NGjt[WFqdmS3Y3XzJJRp\SCpZX7ldoF1cW:wIH;mJIh6\HKxZ3XuJJBmem:6aXTlJIZzd21iNHi= Mo\iNlA3OjRzNkO=
HL-60  MlzoSpVv[3Srb36gRZN{[Xl? M1frWVExNTVyMDDuUS=> NWHzSWpsPCCq NWDNVVJV\GWlcnXhd4V{KHSqZTDobZN1d26nIHTlZYNmfHmuYYPlJEhJTEGFKTDhZ5Rqfmm2edMg NFzCOpMzODZ{NEG2Ny=>
HP100 M{D5N2Z2dmO2aX;uJGF{e2G7 MWGxNE02ODBibl2= MYm0JIg> NITlVHll\WO{ZXHz[ZMhfGinIHjpd5RwdmViZHXhZ4V1gWyjc3WgLGhFSUNrIHHjeIl3cXS7wrC= NHjGVoszODZ{NEG2Ny=>
11z Mm\ET4lv[XOnIFHzd4F6 M4nUcVMuOTByIH7N MoPodoVlfWOnczDISGFEKGWweontZZRq[yCjY4Tpeol1gSBqSVO1NOKhRSB4LkWgxtEhOC54IH7tc4wwVCl? MYmyNFYxPTF2NB?=
SKOV-3 NUKyeVFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HXRlQwQC9zNjDuUS=> MknvOFghcA>? NULGTZpFcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? MmrFNlA1ODR3NkS=
OVCAR-3 M3LlWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXrXWhOPC96L{G2JI5O MVi0PEBp MV3pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> NX;W[pBlOjB2MES1OlQ>
HBL-2 NGnLbWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;0WlIuOTBibl2= NGnGXlYzPCCq NImxb3ZKSzVyPUSuN{BvVQ>? NWjGVGtROjByNkiwPFA>
Jeko-1 NYW5ZpdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIj6WpMzNTVyIH7N MVqyOEBp MX;JR|UxRTFzIH7N MlW2NlAxPjhyOEC=
Granta-519 M3XFN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE[zeWw2NTRyIH7N NX\RW4E2OjRiaB?= NF3SWotKSzVyPUW4MlUhdk1? M{jQNFIxODZ6MEiw
L1236 NGnQSVBEgXSxdH;4bYNqfHliQYPzZZk> MYSxJI5ONTFyMDFOwG0> NIG1UHI1QCCq MXfFR|UxRTBwMEeg{txO MX2xPVI{OzR5MB?=
L428 M{jyfWN6fG:2b4jpZ4l1gSCDc4PhfS=> MWOxJI5ONTFyMDFOwG0> MXu0PEBp MojoSWM2OD1yLkSzJO69VQ>? NGTyTJIyQTJ|M{S3NC=>
KM-H2 M4rDbWN6fG:2b4jpZ4l1gSCDc4PhfS=> MX:xJI5ONTFyMDFOwG0> MWC0PEBp MW\FR|UxRTBwNUig{txO MWqxPVI{OzR5MB?=
L540Cy NFH2dG5EgXSxdH;4bYNqfHliQYPzZZk> NITBcJAyKG6PLUGwNEDPxE1? MWW0PEBp M3HtZmVEPTB;MD6xOkDPxE1? MXGxPVI{OzR5MB?=
G401 NX\wZVRITnWwY4Tpc44hSXO|YYm= MnjYNVAhdk1? NFHQUWQzPC92OD:3NkBp MX;EUXNQ MkfXbY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u M1rWW|E6OjJzNUi2
STM91-01 NF;1NJRHfW6ldHnvckBCe3OjeR?= MYCxNEBvVQ>? NIjHbIYzPC92OD:3NkBp NGCwfpVFVVOR NEe1dHZqdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> NW\RfJB4OTl{MkG1PFY>
SJSC  M4jrRmZ2dmO2aX;uJGF{e2G7 MXKxNEBvVQ>? NHvPNVAzPC92OD:3NkBp MnLZSG1UVw>? MnTFbY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u NXzDT21wOTl{MkG1PFY>
BT16  MVvGeY5kfGmxbjDBd5NigQ>? MWCxNEBvVQ>? M4i3XVI1NzR6L{eyJIg> M1HGSWROW09? MXnpcoNz\WG|ZYOgR2RMVjGFIHX4dJJme3Orb36= NX\EPZlVOTl{MkG1PFY>
NCI-H1299 NH7T[41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUGyTmJMUUN3ME20MlbDuTBwMjDu[{9udA>? MXuxPVE4QTh7MB?=
NCI-2882 MkS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlf6TWM2OD1zLkdCtVAvODRibnevcYw> MkTmNVkyPzl6OUC=
HCC95 M1PzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\1[ZU4UUN3ME2yMlXDuTBwMEWgcocwdWx? MkXDNVkyPzl6OUC=
NCI-H23 NWH3foFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrOWZdkUUN3ME2yMlnDuTBwMjDu[{9udA>? M1fCNlE6OTd7OEmw
NCI-H157 MnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTFwNtMxNE4xOiCwZz;tcC=> MVexPVE4QTh7MB?=
NCI-H460 NW\xblZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTJwMdMxNE4xPyCwZz;tcC=> MYWxPVE4QTh7MB?=
NCI-H1975 M2GxN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTFwM9MxNE4xPCCwZz;tcC=> M3;ocFE6OTd7OEmw
NCI-H820 MmSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIC0OGRKSzVyPUKuOOKyOC5zIH7nM41t NUPRcnpzOTlzN{m4PVA>
NCI-H1650 Mn7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nVdmlEPTB;ND65xtExNjNibnevcYw> NXG1cphwOTlzN{m4PVA>
DTC1 M2DZcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXqZWpKSzVyPUCuOVEhdk1? MYSxPFU3PjJ2Nh?=
KAO MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTBwOUGgcm0> M33JdlE5PTZ4MkS2
SU-CCS-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVT3R3F[UUN3ME2wMlg6KG6P NY\ve4I3OTh3Nk[yOFY>
SYO-1 NIDMS3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jtWGlEPTB;MD62O{BvVQ>? M1vGXVE5PTZ4MkS2
FUJI MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnrZ2NuUUN3ME2xMlMyKG6P NHewWlkyQDV4NkK0Oi=>
SKNMC NGfoU5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PVWWlEPTB;MT6xO{BvVQ>? NVHVdmNpOTh3Nk[yOFY>
402-91 NF7WdpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTFwMk[gcm0> NUDJeHhSOTh3Nk[yOFY>
1765-92 NVn6Sld1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTFwN{egcm0> NVHFXWs4OTh3Nk[yOFY>
JN-DSRCT-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTFwMkWgcm0> NHL3Xm8yQDV4NkK0Oi=>
NMS-2PC M13CXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwOEGgcm0> NFnnNosyQDV4NkK0Oi=>
HL60 Mn7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnFTWM2OD1zLki2JI5O MkK1NVg2PjZ{NE[=
A549 MmK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTNwMkSgcm0> MWexPFU3PjJ2Nh?=
SW480 NYDVV4ZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHkUVh4UUN3ME2yMlY6KG6P MV2xPFU3PjJ2Nh?=
MCF7 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTNwNUWgcm0> NX\jWpRGOTh3Nk[yOFY>
PC-3 NEO2OmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTJwNUGgcm0> M4XhVlE5PTZ4MkS2
MMRU NXzyOXNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnPS41KSzVyPUKuOVchdk1? NYn3c5A4OTh3Nk[yOFY>
Hs68 M{LpR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX:xWm85UUN3ME2+NVAhdk1? NWDu[|R3OTh3Nk[yOFY>
hMSC-001F MonlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PMPWlEPTB;PkGwJI5O Mnu4NVg2PjZ{NE[=

... Click to View More Cell Line Experimental Data

体内研究 与PBS处理的对照组相比,单独使用Erlotinib 和 Romidepsin分别可以对NCI-H1299细胞系的异种移植生长抑制到72% 和 43% ,但是并不具有明显的统计学意义。只有当两种药物联用的时候才会对其生长造成明显的抑制作用,此时生长被抑制到28% [1]。在免疫功能低下的小鼠中,Romidepsin 会抑制皮下NB 异种移植的生长,这种抑制作用具有剂量依赖的特性 。此外, 在NB病人的肿瘤组织中Romidepsin 会诱导某些基因的表达,如 p21 和p75 以及NTRK (TrkA) [2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
细胞实验:[3]
+ 展开
  • Cell lines: NCI-H1975, NCI-H157, NCI-2882, NCI-H460 和 HCC95 细胞系
  • Concentrations: 1 ng/mL
  • Incubation Time: 72 小时
  • Method: 使用MTS法分析药物敏感性。在96孔平板中每孔接种2×103个细胞(包括NCI-H1975, NCI-H157, NCI-2882, NCI-H460和HCC95) 。24小时后, 在存在或者缺少1 ng/mL Romidepsin的条件下将细胞与不同浓度 (0.01 µM - 250 µM) 的Erlotinib 37°C 孵育72 小时。 MTS 溶液加到每个孔中37°C孵育1小时。利用分光光度计测量490 nm 处的光密度值。每种药物浓度的实验都设置8个复孔并重复两次。基于细胞生存曲线的吸光度值计算药物的半抑制浓度 (IC50) 。
    (Only for Reference)
动物实验:[5]
+ 展开
  • Animal Models: 携带NCI-H1299 细胞的 BALB/c无胸腺裸小鼠
  • Formulation: 用PBS配制
  • Dosages: 1.2 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用:
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 540.7
化学式

C24H36N4O6S2

CAS号 128517-07-7
稳定性 powder
别名 FR 901228, NSC 630176

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00048334 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 26, 2002 Phase 1
NCT00094978 Terminated Carcinoma, Small Cell|Carcinoma, Non-Small-Cell Lung|Esophageal Neoplasms|Mesothelioma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 25, 2004 Phase 1
NCT01445340 Terminated Mycosis Fungoides|Cutaneous T-Cell Lymphoma|Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 21, 2007 Phase 1
NCT02616965 Not yet recruiting Cutaneous T-cell Lymphoma (CTCL) Fox Chase Cancer Center|Seattle Genetics, Inc.|Celgene Corporation April 2017 Phase 1
NCT02850016 Recruiting Human Immunodeficiency Virus (HIV) Rockefeller University|University Hospital of Cologne|Aarhus University Hospital December 2016 Phase 2
NCT02757248 Withdrawn PTCL|CTCL Anne Beaven, MD|National Comprehensive Cancer Network|Boehringer Ingelheim|Duke University November 2016 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品

Tags: 购买Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)供应商 | 采购Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)价格 | Romidepsin (FK228, Depsipeptide)生产 | 订购Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID